Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
45 participants
INTERVENTIONAL
2004-01-31
2010-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bone Healing After Dental Extraction in Postmenopausal Osteoporotic Women Treated With Alendronate Per os Weekly
NCT01648686
Comparison of the Effect of an Ongoing Treatment With Alendronate or a Drug Holiday on the Fracture Risk in Osteoporotic Patients With Bisphosphonate Long Term Therapy
NCT01512446
Alendronate Prevents Microarchitectural Deterioration of Trabecular Bone in Early Postmenopausal Women
NCT00504166
Safety/Efficacy of Zoledronic Acid and Alendronate on Bone Metabolism in Postmenopausal Women With Osteoporosis
NCT00404820
Osteoporosis Prevention With Low Dose Alendronate
NCT00463268
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily, dental implant
alendronate once weekly 70mg
alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
2
placebo once weekly, calcium 1000mg and Vitamin D 800 IU daily; dental implant
placebo
placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
3
dental implant, calcium 1000mg and Vitamin D 800 IU daily
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
alendronate once weekly 70mg
alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
placebo
placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age between 60 and 75 years
* Possibility to insert a dental implant
* Osteoporosis as defined by WHO criteria (intervention group), or women without osteoporosis / osteopenia (non-intervention group)
Exclusion Criteria
* Chronic inflammatory rheumatoid disease
* Bisphosphonate treatments during the last 12 months
* Inflammatory or metabolic bone disease, excluding osteoporosis
* Systemic corticosteroid treatments of more than one month within previous 12 months
* Severe diseases with life expectancy less than one year or expectation of rapid worsening within one year
60 Years
75 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Charite University, Berlin, Germany
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Center for Muscle and Bone Research
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dieter Felsenberg, Prof. D.r
Role: STUDY_CHAIR
Leader of the center for muscle and bone research, Charité
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Muscle and Bone Research, Charité - Campus Benjamin Franklin
Berlin, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Dieter Felsenberg, Prof. Dr.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OPOZAHN
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.